Acute but not chronic donepezil increases muscarinic receptor-mediated signaling via arachidonic acid in unanesthetized rats

Journal of Alzheimer's Disease

Volumn 17, Issue 2, 2009, Pages 369-382

  Basselin, Mireille ^a   Nguyen, Henry N ^a   Chang, Lisa ^a   Bell, Jane M ^a   Rapoport, Stanley I ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Acetylcholine; Acetylcholinesterase; Alzheimer's disease; Anticholinesterase; Arachidonic acid; Brain; Desensitization; Donepezil; Imaging; Muscarinic receptors; Phospholipase A2

Indexed keywords

ACETYLCHOLINE; ARACHIDONIC ACID; ARECOLINE; ATROPINE; CHOLINESTERASE; CYTOSOLIC PHOSPHOLIPASE A2; DONEPEZIL; MUSCARINIC RECEPTOR;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; ENZYME ACTIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

EID: 67849114602     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2009-1058     Document Type: Article

References (79)

1. Benjamin B, Burns A (2007) Donepezil for Alzheimer's disease. Expert Rev Neurother 7, 1243-1249.
2. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, DeLong MR (1982) Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 215, 12371239.
3. Atack JR, Perry EK, Bonham JR, Perry RH, Tomlinson BE, Blessed G, Fairbairn A (1983) Molecular forms of acetyl-cholinesterase in senile dementia of the Alzheimer type: Selective loss of the intermediate (10S) form. Neurosci Lett 40, 199-204.
4. Bartus RT, Dean RL, 3rd, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217, 408-414.
5. Seltzer B (2007) Donepezil: an update. Expert Opin Pharmacother 8, 1011-1023.
6. Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, Sun Y, Perdomo CA, Richardson S (2007) Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 69, 459-469.
7. Wallin AK, Andreasen N, Eriksson S, Batsman S, Nasman B, Ekdahl A, Kilander L, Grut M, Ryden M, Wallin A, Jonsson M, Olof sson H, Londos E, Wattmo C, Eriksdotter Jonhagen M, Minthon L (2007) Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting. Dement Geriatr Cogn Disord 23, 150-160.
8. Bullock R, Dengiz A (2005) Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years. Int J Clin Pract 59, 817-822.
9. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, Edwards S, Hardyman W, Raftery J, Crome P, Lendon C, Shaw H, Bentham P (2004) Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 363, 2105-2115.
10. Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, Burns AS, Holmes C, Jacoby R, Johnson T, Knapp M, Lindesay J, O'Brien JT, Wilcock G, Katona C, Jones RW, DeCesare J, Rodger M (2007) Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 357, 13821392.
11. Raschetti R, Albanese E, Vanacore N, Maggini M (2007) Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med 4, e338.
12. Jack CR, Jr., Petersen RC, Grundman M, Jin S, Gamst A, Ward CP, Sencakova D, Doody RS, Thal LJ (2008) Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging 29, 1285-1295.
13. Kosasa T, Kuriya Y, Matsui K, Yamanishi Y (1999) Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats. Eur J Pharmacol 380, 101-107.
14. Scali C, Casamenti F, Bellucci A, Costagli C, Schmidt B, Pepeu G (2002) Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats. J Neural Transm 109, 1067-1080.
15. Haug KH, Bogen IL, Osmundsen H, Walaas I, Fonnum F (2005) Effects on cholinergic markers in rat brain and blood after short and prolonged administration of donepezil. NeurochemRes 30, 1511-1520.
16. Barnes CA, Meltzer J, Houston F, Orr G, McGann K, Wenk GL (2000) Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience 99, 17-23.
17. Reid RT, Sabbagh MN (2003) Effects of donepezil treatment on rat nicotinic acetylcholine receptor levels in vivo and in vitro. J Alzheimers Dis 5, 429-436.
18. Cutuli D, Foti F, Mandolesi L, Bartolo PD, Gelfo F, Federico F, Petrosini L (2008) Cognitive performance of healthy young rats following chronic donepezil administration. Psychophar- macology (Berl) 197, 661-673.
19. Clayton BA, Hayashida K, Childers SR, Xiao R, Eisenach JC (2007) Oral donepezil reduces hypersensitivity after nerve injury by a spinal muscarinic receptor mechanism. Anesthesiology 106, 1019-1025.
20. Clark JD, Schievella AR, Nalefski EA, Lin LL (1995) Cytoso- lic phospholipase A2. J Lipid Mediat Cell Signal 12, 83-117.
21. Bayon Y, Hernandez M, Alonso A, Nunez L, Garcia-Sancho J, Leslie C, Sanchez Crespo M, Nieto ML (1997) Cytosolic phospholipase A2is coupled to muscarinic receptors in the human astrocytoma cell line 1321N1: characterization of the transducing mechanism. Biochem J 323, 281-287.
22. Felder CC, Dieter P, Kinsella J, Tamura K, Kanterman RY, Axelrod J (1990) Atransfected 1115muscarinic acetylcholine receptor stimulates phospholipase A2by inducing both calcium influx and activation of protein kinase C. J Pharmacol Exp Ther 255, 1140-1147.
23. Basselin M, Chang L, Seemann R, Bell JM, Rapoport SI (2003) Chronic lithium administration potentiates brain arachidonic acid signaling at rest and during cholinergic activation in awake rats. JNeurochem 85, 1553-1562.
24. Basselin M, Villacreses NE, Langenbach R, Ma K, Bell JM, Rapoport SI (2006) Resting and arecoline-stimulated brain metabolism and signaling involving arachidonic acid are altered in the cyclooxygenase-2 knockout mice. J Neurochem 96, 669-679.
25. Basselin M, Villacreses NE, Lee H-J, Bell JM, Rapoport SI (2007) Flurbiprof en, a cyclooxygenase inhibitor, reduces the brain arachidonic acid signal in response to the cholinergic muscarinic, arecoline, in awake rats. Neurochem Res 32, 18571867.
26. DeGeorge JJ, Nariai T, Yamazaki S, Williams WM, Rapoport SI (1991) Arecoline-stimulated brain incorporation of intravenously administered fatty acids in unanesthetized rats. J Neurochem 56, 352-355.
27. 14 C]arachidonate in awake rats, with or without cholinergic stimulation, following unilateral lesioning of nucleus basalis magnocellularis. Brain Res 559, 1-9.
28. Robinson PJ, Noronha J, DeGeorge JJ, Freed LM, Nariai T, Rapoport SI (1992) A quantitative method for measuring regional in vivo fatty-acid incorporation into and turnover within brain phospholipids: Review and critical analysis. Brain Res Brain Res Rev 17, 187-214.
29. Rapoport SI (2003) In vivo approaches to quantifying and imaging brain arachidonic and docosahexaenoic acid metabolism. J Pediatr 143, S26-34.
30. Rapoport SI, Chang MC, Spector AA (2001) Delivery and turnover of plasma-derived essential PUFAs in mammalian brain. J Lipid Res 42, 678-685.
31. 11C]-arachidonate in normocapnic and hypercapnic monkeys, measured with positron emission tomography. Brain Res 755, 74-83.
32. Bosetti F (2007) Arachidonic acid metabolism in brain physiology and pathology: lessons from genetically altered mouse models. J Neurochem 102, 577-586.
33. Matsui K, Mishima M, Nagai Y, Yuzuriha T, Yoshimura T (1999) Absorption, distribution, metabolism, and excretion of donepezil (Aricept) after a single oral administration to Rat. Drug Metab Dispos 27, 1406-1414.
34. DeMar JJ, Lee HJ, Ma K, Chang L, Bell JM, Rapoport SI, Bazinet RP (2006) Brain elongation of linoleic acid is a negligible source of the arachidonate in brain phospholipids of adult rats. Biochim Biophys Acta 1761, 1050-1059.
35. Brezenof f HE, Xiao YF, Vargas H (1988) A comparison of the central and peripheral antimuscarinic effects of atropine and methylatropine injected systemically and into the cerebral ventricles. Life Sci 42, 905-911.
36. Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. Biol Chem 226, 497-509.
37. 14C]arachidonate to examine regional brain lipid metabolism in unanesthetized rats. Neurosci Res 24, 413-423.
38. Paxinos G, Watson C (1987) The rat brain in stereotaxic coordinates, Academic Press, New York.
39. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248-254.
40. Stavinoha WB, Weintraub ST, Modak AT (1973) The use of microwave heating to inactivate cholinesterase in the rat brain prior to analysis for acetylcholine. Neurochem 20, 361-371.
41. Motulsky H (2003) Prism 4 Statistics Guide-Statistical analyses for laboratory and clinical researchers. GraphPad Software Inc., San Diego.
42. Dronfield S, Egan K, Marsden CA, Green AR (2000) Comparison of donepezil-, tacrine-, rivastigmine- and metrifonate- induced central and peripheral cholinergically mediated responses in the rat. Psychopharmacol 14, 275-279.
43. Janowsky DS, Risch SC (1984) Cholinomimetic and anti-cholinergic drugs used to investigate an acetylcholine hypothesis of affective disorders and stress. Drug Dev Res 4, 125-142.
44. Kousba AA, Poet TS, Timchalk C (2003) Characterization of the in vitro kinetic interaction of chlorpyrifos-oxon with rat salivary cholinesterase: a potential biomonitoring matrix. Toxicology 188, 219-232.
45. Lippa AS, Critchett DJ, Joseph JA (1986) Desensitization of muscarinic acetylcholine receptors: possible relation to receptor heterogeneity and phosphoinositides. Brain Res 366, 98-105.
46. Maloteaux JM, Hermans E (1994) Agonist-induced muscarinic cholinergic receptor internalization, recycling and degradation in cultured neuronal cells. Cellular mechanisms and role in desensitization. Biochem Pharmacol 47, 77-88.
47. Baumgold J, Cooperman BB, White TM (1989) Relationship between desensitization and sequestration of muscarinic cholinergic receptors in two neuronal cell lines. Neuropharmacology 28, 1253-1261.
48. Fisher SK (1988) Recognition of muscarinic cholinergic receptors in human SK-N-SH neuroblastoma cells by quaternary and tertiary ligands is dependent upon temperature, cell integrity, and the presence of agonists. Mol Pharmacol 33, 414-422.
49. Thompson AK, Fisher SK (1991) Preferential coupling of cell surface muscarinic receptors to phosphoinositide hydrolysis in human neuroblastoma cells. Biol Chem 266, 5004-5010.
50. 3H]N-methylscopolamine in mouse brain following acute treatment with an organophosphate. Eur J Pharmacol 132, 147-154.
51. Tang J, Carr RL, Chambers JE (1999) Changes in rat brain cholinesterase activity and muscarinic receptor density during and after repeated oral exposure to chlorpyrifos in early postnatal development. Toxicol Sci 51, 265-272.
52. Harden TK, Petch LA, Traynelis SF, Waldo GL (1985) Agonist-induced alteration in the membrane form of muscarinic cholinergic receptors. JBiol Chem 260, 13060-13066.
53. Darreh-Shori T, Meurling L, Pettersson T, Hugosson K, Hellstrom-Lindahl E, Andreasen N, Minthon L, Nordberg A (2006) Changes inthe activityand proteinlevels of CSF acetyl-cholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment. J Neural Transm 113, 1791-1801.
54. Hatip-Al-Khatib I, Iwasaki K, Yoshimitsu Y, Arai T, Egashira N, Mishima K, Ikeda T, Fujiwara M (2005) Effect of oral administration of zanapezil (TAK-147) for 21 days on acetyl- choline and monoamines levels in the ventral hippocampus of freely moving rats. Br J Pharmacol 145, 1035-1044.
55. Moriguchi S, Zhao X, Marszalec W, Yeh JZ, Narahashi T (2005) Modulation of N-methyl-D-aspartate receptors by donepezil in rat cortical neurons. J Pharmacol Exp Ther 315, 125-135.
56. FelderCC, Kanterman RY, Ma AL, Axelrod J(1990) Serotonin stimulates phospholipase A2and the release of arachidonic acid in hippocampal neurons by a type 2 serotonin receptor that is independent of inositolphospholipid hydrolysis. Proc Natl Acad Sci USA 87, 2187-2191.
57. Vial D, Piomelli D (1995) Dopamine D2receptors potentiate arachidonate release via activation of cytosolic, arachidonic-specific phospholipase A2. J Neurochem 64, 2765-2772.
58. Weichel O, Hilgert M, Chatterjee SS, Lehr M, Klein J (1999) Bilobalide, a constituent of Ginkgo biloba, inhibits NMDA-induced phospholipase A2activation and phospholipid breakdown in rat hippocampus. Naunyn Schmiedebergs Arch Pharmacol 360, 609-615.
59. Marshall DL, Redfern PH, Wonnacott S (1997) Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: comparison of naive and chronic nicotine-treated rats. J Neurochem 68, 1511-1519.
60. Marin, P., Hamon B, Glowinski J, Premont J (1997) Nicotine- induced inhibition of neuronal phospholipase A2. JPharmacol ExpTher 280, 1277-1283.
61. Chang L, Rapoport SI, Nguyen HN, Greenstein D, Chen M, Basselin M (2009) Acute nicotine reduces brain arachidonic acid signaling in unanesthetized rats. J Cereb Blood Flow Metab 29, 648-658.
62. Kiefer-Day JS, el-Fakahany EE (1992) Muscarinic receptor function and acetylcholinesterase activity after chronic administration of tacrine to mice at therapeutic drug concentrations. Pharmacology 44, 71-80.
63. Abdallah EA, el-Fakahany EE (1991) Lack of desensitization of muscarinic receptor-mediated second messenger signals in rat brain upon acute and chronic inhibition of acetyl-cholinesterase. J Biochem Toxicol 6, 261-268.
64. Hinz VC, Kolb J, Schmidt BH (1998) Effects of subchronic administration of metrifonate on cholinergic neurotransmission in rats. Neurochem Res 23, 931-938.
65. Barik J, Dajas-Bailador F, Wonnacott S (2005) Cellular responses to nicotinic receptor activation are decreased after prolonged exposure to galantamine in human neuroblastoma cells. Br J Pharmacol 145, 1084-1092.
66. Li B, Duysen EG, Volpicelli-Daley LA, Levey AI, Lockridge O (2003) Regulation of muscarinic acetylcholine receptor function in acetylcholinesterase knockout mice. Pharmacol Biochem Behav 74, 977-986.
67. Svedberg MM, Bednar I, Nordberg A (2004) Effect of subchronic galantamine treatment on neuronal nicotinic and mus- carinic receptor subtypes in transgenic mice overexpress- ing human acetylcholinesterase. Neuropharmacology 47, 558571.
68. Lee HJ, Rao JS, Ertley RN, Chang L, Rapoport SI, Bazinet RP (2007) Chronic fluoxetine increases cytosolic phospholipase A2activity and arachidonic acid turnover in brain phospholipids of the unanesthetized rat. Psychopharmacology (Berl) 190, 103-115.
69. Qu Y, Chang L, Klaff J, Seemann R, Greenstein D, Rapoport SI (2006) Chronic fluoxetine upregulates arachidonic acid incorporation into the brain of unanesthetized rats. Eur Neuropsychopharmacol 16, 561-571.
70. Lee HJ, Rao JS, Chang L, Rapoport SI, Bazinet RP (2008) Chronic N-methyl-D-aspartate administration increases the turnover of arachidonic acid within brain phospholipids of the unanesthetized rat. J Lipid Res 49, 162-168.
71. Rao JS, Ertley RN, Rapoport SI, Bazinet RP, Lee HJ (2007) Chronic NMDA administration to rats up-regulates frontal cortex cytosolic phospholipase A2and its transcription factor, activator protein-2. J Neurochem 102, 1918-1927.
72. Levey AI (1993) Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci 52, 441-448.
73. Borea PA, Varani K, Gessi S, Merighi S, Dal Piaz A, Gilli P, Gilli G (2004) Receptor binding thermodynamics at the neuronal nicotinic receptor. Curr Top Med Chem 4, 361-368.
74. Greenberg SM, Tennis MK, Brown LB, Gomez-Isla T, Hay- den DL, Schoenfeld DA, Walsh KL, Corwin C, Daffner KR, Friedman P, Meadows ME, Sperling RA, Growdon JH (2000) Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol 57, 94-99.
75. Leber P (1996) Observations and suggestions on antidementia drug development. Alzheimer Dis Assoc Disord 10 Suppl 1, 31-35.
76. Flynn DD, Weinstein DA, Mash DC (1991) Loss of high- affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: implications for the failure of choliner- gic replacement therapies. Ann Neurol 29, 256-262.
77. Tsang SW, Pomakian J, Marshall GA, Vinters HV, Cummings JL, Chen CP, Wong PT, Lai MK (2007) Disrupted muscarinic M1 receptor signaling correlates with loss of protein kinase C activity and glutamatergic deficit in Alzheimer's disease. Neurobiol Aging 28, 1381-1387.
78. Akaike A (2006) Preclinical evidence of neuroprotection by cholinesterase inhibitors. Alzheimer Dis Assoc Disord 20, S8-11.
79. Jacobson SA, Sabbagh MN (2008) Donepezil: potential neuroprotective and disease-modifying effects. Expert Opin Drug Metab Toxicol 4, 1363-1369.